Glenmark Pharmaceuticals receives ANDA approval for Hydrocortisone Valerate Cream USP, 0.2%
Deepthi | Myequity news | Date : 15-10-2018 12:00:00 IST
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Hydrocortisone Valerate Cream USP, 0.2%, a generic version of Westcort® Cream, 0.2%, of Sun Pharmaceutical Industries Inc.
According to IQVIATM sales data for the 12-month period ending August 2018, the Westcort® Cream, 0.2% market2 achieved annual sales of approximately $17.0 million.
About Glenmark Pharmaceuticals:
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory. The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.